Immunosenescence profile and expression of the aging biomarker (p16INK4a) in testicular cancer survivors treated with chemotherapy

Velazquez, Hugo E.; Hinojosa, Juan; Orozco, Luis; Rios-Corzo, Ricardo; Lima, Guadalupe; Llorente, Luis; Hernandez-Ramirez, Diego F.; Valentin-Cortez, Francisco J.; Medina-Rangel, Irene; Atisha-Fregoso, Yemil

doi:10.1186/s12885-020-07383-2

Immunosenescence profile and expression of the aging biomarker (p16INK4a) in testicular cancer survivors treated with chemotherapy

Journal

BMC Cancer

ISSN

1471-2407

Date Issued

2020

Author(s)

Velazquez, Hugo E.

Facultad de Ciencias de la Salud - CampCM

Hinojosa, Juan

Orozco, Luis

Rios-Corzo, Ricardo

Lima, Guadalupe

Llorente, Luis

Hernandez-Ramirez, Diego F.

Valentin-Cortez, Francisco J.

Medina-Rangel, Irene

Atisha-Fregoso, Yemil

Type

text::journal::journal article

DOI

10.1186/s12885-020-07383-2

URL

https://scripta.up.edu.mx/handle/20.500.12552/2134

Abstract

Background: Cytotoxic chemotherapy can cure advanced germ cell tumors. Nevertheless, cancer treatment may induce cellular senescence and accelerate molecular aging. The aging process implies an increase of cells expressing p16INK4a and changes in lymphocyte subpopulations. Our aim was to study the potential induction of premature immunosenescence in testicular cancer survivors (TCS) exposed to chemotherapy. Methods: Case-control exploratory study of TCS treated with chemotherapy (≥3 BEP cycles, disease-free ≥3 months) compared with age matched healthy controls. Peripheral blood mononuclear cells were isolated, and lymphocyte subpopulations were analyzed by flow cytometry. CDKN2A/p16INK4a expression in T cells was measured using qPCR. The percentage of lymphocyte subpopulations and the CDKN2A/p16INK4a expression in TCS were compared with the control group using the Wilcoxon signed-rank test.